When administered alone or in combination with PD-1 blockade, this vaccine elicited strong tumor-specific CD4+ and CD8+ T cell responses, reinforcing the therapeutic potential of RNA vaccines in melanoma immunotherapy [139]. The gene discussed is CD4; the disease is neoplasm.